Galenica says FDA approves supplemental new drug application for Veltassa
Monday, November 28, 2016
FDA approves supplemental new drug application (SNDA) for Veltassa removing boxed warning regarding drug-drug interactions. Approval reinforces potential of Veltassa as a key platform of additional growth for Vifor Pharma.
Vifor Pharma to make necessary investments to achieve veltassa's significant mid-term potential.
Relypsa, Inc., a Vifor Pharma company, has received approval from FDA for a SNDA with important updates to us label of Veltassa (patiromer) for oral suspension.
Source : reuters.com
